

ASSESSMENT OF THE ROLE OF THE LEU28PRO POLYMORPHIC MARKER OF THE APOE GENE IN DIABETIC NEPHROPATHY

Jabbarov O.O*; Khujaniyazova N. K**

*Associate Professor,
Head of the Department of Faculty and Hospital Therapy,
UZBEKISTAN
Email id: dok_azim66@mail.ru

**Chilanzar College of Public Health named after Abu Ali ibn Sina,
UZBEKISTAN
Email id: teacher1201@mail.ru

DOI: **10.5958/2249-7137.2022.00022.2**

ABSTRACT

The aim of this study was to study 129 patients with type 2 diabetes and 110 healthy people to determine whether the Leu28Pro polymorphic markers of the APOE gene are associated with the development of diabetic nephropathy (DN). Patients in the main group: 65 patients with a disease duration of up to 10 years, without diabetic nephropathy (33 patients) and with diabetic nephropathy (32 patients), 64 patients with diabetes lasting more than 10-20 years, with no diabetic nephropathy (31 patients) and diabetic nephropathy (33 patients). Genotyping was carried out by polymerase chain reaction. The study showed that the association of the Pro allele and the Leu/Pro genotype of the ENOS3 gene play a role in the development of diabetic nephropathy in patients with type 2 diabetes mellitus in the studied Uzbek nation.

KEYWORDS: *Diabetic Nephropathy, Diabetes Mellitus, Gene, Polymorphism, Allele, Genotype.*

REFERENCES

1. Jabbarov OO. Features of Genetic polymorphism in population with diabetic nephropathia: Literature review. Journal of advances in medicine and medical research 2019;29(9):1-7.
 2. Alberti G, Zimmet P, Shaw J. IDF. Epidemiology Task fores consensus group. The metabolic syndrome - a new worldwide definition. Lancet. 2005;366:1059-1062.
 3. Jeleznyakova AV, Lebedeva NO, Vikulova OK, et al. The risk of developing chronic kidney disease in patients with type 2 diabetes mellitus is determined by polymorphism of the NOS3, APOB, KCNJ11, TCF7L2 genes. Diabetes mellitus. 2014;(3):23-30.
 4. Jabbarov OO. Significance of the RAAS coding component of the ACE gene in the development of diabetic nephropathy in type 2 diabetes. Infection, immunity and pharmacology. 2019;(6): 47-55.
-

5. Vikulova OK. Clinical, laboratory and genetic factors for the development and progression of diabetic nephropathy in patients with type 1 diabetes mellitus: Diss. ...Cand. honey. Sciences: Vikulova Olga Konstantinovna, Mascow; 2003. 123 p.
6. Kuchkarova DT. Analysis of energy-saving modes of pumping machines and units at industrial enterprises. Problems of modern science and education. 2020;(1):146.
7. Kuchkarova DT. Energy-Saving Control Systems of Machines and Silk-Winding Units. 2021. p. 92.
8. Shestakova MV, Shakhmalova MSh. Diabetic nephropathy: clinical picture, diagnosis, treatment. Moscow; 2009.
9. Villeneuve S, Brisson D, Marchant N, Gaudet D. The potential applications of Apolipoprotein E in personalized medicine. *Frontiers in Aging Neuroscience*. 2014;6:154.
10. Koopal C, van der Graaf Y, Asselbergs F, Westerink J, Visseren F. Influence of APOE-2 genotype on the relation between adiposity and plasma lipid levels in patients with vascular disease. *Int J Obes Relat Metab Disord*. 2015;39(2):265–269